Literature DB >> 22307943

Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry.

Sangmee Bae1, Rajeev Saggar, Marcy B Bolster, Lorinda Chung, Mary Ellen Csuka, Chris Derk, Robyn Domsic, Aryeh Fischer, Tracy Frech, Avram Goldberg, Monique Hinchcliff, Vivien Hsu, Laura Hummers, Elena Schiopu, Maureen D Mayes, Vallerie McLaughlin, Jerry Molitor, Nausheen Naz, Daniel E Furst, Paul Maranian, Virginia Steen, Dinesh Khanna.   

Abstract

BACKGROUND: Patients with normal (mean pulmonary arterial pressure (mPAP) ≤20 mm Hg) and borderline mean pulmonary pressures (21-24 mm Hg) are "at risk" of developing pulmonary hypertension (PH). The objectives of this analysis were to examine the baseline characteristics in systemic sclerosis (SSc) with normal and borderline mPAP and to explore long-term outcomes in SSc patients with borderline mPAP versus normal haemodynamics.
METHODS: PHAROS is a multicentre prospective longitudinal cohort of patients with SSc "at risk" or recently diagnosed with resting PH on right heart catheterisation (RHC). Baseline clinical characteristics, pulmonary function tests, high-resolution CT, 2-dimensional echocardiogram and RHC results were analysed in normal and borderline mPAP groups.
RESULTS: 206 patients underwent RHC (results showed 35 normal, 28 borderline mPAP, 143 resting PH). There were no differences in the baseline demographics. Patients in the borderline mPAP group were more likely to have restrictive lung disease (67% vs 30%), fibrosis on high-resolution CT and a higher estimated right ventricular systolic pressure on echocardiogram (46.3 vs 36.2 mm Hg; p<0.05) than patients with normal haemodynamics. RHC revealed higher pulmonary vascular resistance and more elevated mPAP on exercise (≥30; 88% vs 56%) in the borderline mPAP group (p<0.05 for both). Patients were followed for a mean of 25.7 months and 24 patients had a repeat RHC during this period. During follow-up, 55% of the borderline mPAP group and 32% of the normal group developed resting PH (p=NS).
CONCLUSIONS: Patients with borderline mPAP have a greater prevalence of abnormal lung physiology, pulmonary fibrosis and the presence of exercise mPAP ≥30 mm Hg.

Entities:  

Mesh:

Year:  2012        PMID: 22307943      PMCID: PMC3398226          DOI: 10.1136/annrheumdis-2011-200546

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

1.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

Review 2.  The lung in systemic sclerosis.

Authors:  Virginia D Steen
Journal:  J Clin Rheumatol       Date:  2005-02       Impact factor: 3.517

3.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

4.  Determinants of pulmonary arterial hypertension in scleroderma.

Authors:  Sotiris C Plastiras; Stylianos P Karadimitrakis; Christos Kampolis; Haralampos M Moutsopoulos; George E Tzelepis
Journal:  Semin Arthritis Rheum       Date:  2007-01-03       Impact factor: 5.532

5.  Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I).

Authors:  Nicholas Collins; Bruce Bastian; Laurent Quiqueree; Carol Jones; Renae Morgan; Glenn Reeves
Journal:  Eur J Echocardiogr       Date:  2006-01-20

6.  Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma.

Authors:  M Luay Alkotob; Peyman Soltani; Mohammad A Sheatt; Manny C Katsetos; Naomi Rothfield; W David Hager; Raymond J Foley; David I Silverman
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

7.  Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis.

Authors:  Virginia Steen; Maria Chou; Victoria Shanmugam; Martin Mathias; Tunay Kuru; Richard Morrissey
Journal:  Chest       Date:  2008-04-10       Impact factor: 9.410

8.  Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma.

Authors:  Betty Chang; Lionel Schachna; Barbara White; Fredrick M Wigley; Robert A Wise
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

9.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

Authors:  A M Stupi; V D Steen; G R Owens; E L Barnes; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1986-04

10.  Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.

Authors:  Virginia D Steen; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  J Rheumatol       Date:  2007-10-15       Impact factor: 4.666

View more
  29 in total

Review 1.  Definition, epidemiology and registries of pulmonary hypertension.

Authors:  R Awdish; H Cajigas
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.

Authors:  Dinesh Khanna; Heather Gladue; Richard Channick; Lorinda Chung; Oliver Distler; Daniel E Furst; Eric Hachulla; Marc Humbert; David Langleben; Stephen C Mathai; Rajeev Saggar; Scott Visovatti; Nezam Altorok; Whitney Townsend; John FitzGerald; Vallerie V McLaughlin
Journal:  Arthritis Rheum       Date:  2013-12

Review 3.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

4.  Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.

Authors:  Keita Ninagawa; Masaru Kato; Hiroyuki Nakamura; Nobuya Abe; Michihito Kono; Yuichiro Fujieda; Kenji Oku; Shinsuke Yasuda; Hiroshi Ohira; Ichizo Tsujino; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2019-07-06       Impact factor: 2.631

5.  Altered synchrony of right ventricular contraction in borderline pulmonary hypertension.

Authors:  Bouchra Lamia; Jean-François Muir; Luis-Carlos Molano; Catherine Viacroze; Jacques Benichou; Philippe Bonnet; Jean Quieffin; Antoine Cuvelier; Robert Naeije
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-19       Impact factor: 2.357

6.  Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure.

Authors:  Gustavo A Heresi; Omar A Minai; Adriano R Tonelli; Jeffrey P Hammel; Samar Farha; Joseph G Parambil; Raed A Dweik
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

7.  Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis.

Authors:  Sara Jaafar; Scott Visovatti; Amber Young; Suiyuan Huang; Paul Cronin; Dharshan Vummidi; Vallerie McLaughlin; Dinesh Khanna
Journal:  Eur Respir J       Date:  2019-08-22       Impact factor: 16.671

8.  Is early diagnosis of pulmonary arterial hypertension possible in inflammatory rheumatic diseases? Experience from a single center in Turkey.

Authors:  Ali Akdoğan; Sercan Okutucu; Levent Kılıç; Barış Kaya; Banu Evranos; Kudret Aytemir; Lütfi Çöplü; İhsan Ertenli; Meral Çalgüneri; Ali Oto; Lale Tokgözoğlu
Journal:  Eur J Rheumatol       Date:  2015-03-01

Review 9.  The role of imaging in pulmonary hypertension.

Authors:  Meenal Sharma; Andrew T Burns; Kelvin Yap; David L Prior
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

Review 10.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.